Neil Kumar, BridgeBio CEO at BIO22 (J.T. MacMillan Photography for Endpoints News)
August 28, 2023 06:37 AM EDTUpdated 10:56 AM
R&D

Up­dat­ed: Bridge­Bio's AT­TR-CM drug bests place­bo in de­tailed PhI­II da­ta, bol­ster­ing plans for NDA

Katherine Lewin

News Reporter

Bridge­Bio pre­sent­ed de­tailed pos­i­tive da­ta from its Phase III tri­al of aco­ramidis in pa­tients with transthyretin amy­loid car­diomy­opa­thy (AT­TR-CM) at the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times